Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 10/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | KCNJ6 | P48051 | 5/20 | 0.38 |
| ▸ | KCNJ3 | P48549 | 5/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.36 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905446 | 0.86 | TP53 (0.41) | PDE10ABRD4CREBBPJAK1JAK2 | |
| SCHEMBL4911073 | 0.84 | SMN1; SMN2 (0.47) | PDE10ABRD4CREBBP | |
| SCHEMBL2826373 | 0.77 | KCNJ6 (0.36) | PDE10ABRD4CREBBPKCNJ6KCNJ3 | |
| SCHEMBL27690433 | 0.76 | PDE10A (0.35) | PDE10ABRD4CREBBPKCNJ6KCNJ3 | |
| SCHEMBL4714665 | 0.75 | KCNJ6 (0.48) | KCNJ6KCNJ3JAK1JAK2KCNJ5 | |
| SCHEMBL4908203 | 0.74 | MAPK1 (0.39) | PDE10A | |
| SCHEMBL27596969 | 0.70 | KCNJ6 (0.47) | KCNJ6KCNJ3JAK1JAK2KCNJ5 | |
| SCHEMBL14401146 | 0.70 | JAK2 (0.43) | KCNJ6KCNJ3JAK1JAK2KCNJ5 | |
| SCHEMBL4905897 | 0.69 | HPGD (0.48) | — | |
| SCHEMBL4900489 | 0.69 | GRM5 (0.44) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101133027-B | Pyridine-2-carboxamide derivatives as mglur5 antagonists | HOFFMANN LA ROCHE | 2011-03-30 | — | — | CN | claimed |
| US-20080269256-A1 | PYRIDINE-2-CARBOXYAMIDE DERIVATIVES | JAESCHKE GEORG | 2008-10-30 | — | — | US | claimed |
| US-7414060-B2 | Pyridine-2-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | claimed |
| CN-101133027-A | Pyridine-2-carboxamide derivatives as mglur5 antagonists | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | CN | claimed |
| EP-1858854-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2007-11-28 | — | — | EP | claimed |
| WO-2006094639-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | claimed |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | HOFFMANN-LA ROCHE INC. | 2006-09-07 | — | — | US | claimed |
| EP-1858854-B1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-05-07 | — | — | EP | disclosed |
| CN-101133027-B | Pyridine-2-carboxamide derivatives as mglur5 antagonists | HOFFMANN LA ROCHE | 2011-03-30 | — | — | CN | disclosed |
| US-20080269256-A1 | PYRIDINE-2-CARBOXYAMIDE DERIVATIVES | JAESCHKE GEORG | 2008-10-30 | — | — | US | disclosed |
| US-7414060-B2 | Pyridine-2-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| CN-101133027-A | Pyridine-2-carboxamide derivatives as mglur5 antagonists | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | CN | disclosed |
| EP-1858854-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094639-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | HOFFMANN-LA ROCHE INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269256-A1 | PYRIDINE-2-CARBOXYAMIDE DERIVATIVES | CNR2, CNR1, CHRNA2 | PDE10A 397/4885BRD4 603/4885CREBBP 1150/4885 |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | GRM3, GRM2, GRM1 | PDE10A 2167/4885BRD4 1063/4885CREBBP 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.